Latest Financial Results
FY 2022
Fiscal Year Ended Dec 31, 2022
Latest 10-K
View Latest 10-K
Stock Information
Company Overview
Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar is building a drug development pipeline through the licensing and acquisition of oncology therapeutics in late preclinical and clinical development stages, leveraging its scientific and clinical expertise to help reduce the risk and accelerate the clinical development of its drug product candidates. Monopar currently has three compounds in development: Validive® (clonidine HCI MBT), a Phase 2b/3 mucoadhesive buccal tablet for the prevention and treatment of radiation-induced severe oral mucositis (SOM) in oropharyngeal cancer (OPC) patients; camsirubicin (MNPR-201; formerly GPX-150), a proprietary Phase 1b clinical-stage analog of doxorubicin engineered specifically to retain anticancer activity while minimizing toxic effects on the heart; MNPR-101 RIT, a preclinical-stage radio-immuno-therapeutic (RIT) for the treatment of advanced solid cancers and severe COVID-19; MNPR-101 (formerly huATN-658), a late stage preclinical humanized monoclonal antibody, which targets the urokinase plasminogen activator receptor (uPAR) for the treatment of advanced cancers; and MNPR-202, a proprietary early-stage potent camsirubicin analog in various cancers.
Investor Contact Information
Company
Monopar Therapeutics Inc.
1000 Skokie Blvd.
Suite 350
Wilmette, IL 60091
T: (847) 388-0349
info@monopartx.com